Why Columbia Laboratories Collapsed
Most Popular - Before noon, shares of Columbia Laboratories (NASDAQ:CBRX) have already exchanged hands at more than ten times average volume, and the stock is down 40%. The … Continue Reading
Read nowAuthor Archives: Jake King
More Money, Same Problems; OREX Gains on Public Offering
Quick Picks - Word from Orexigen Therapeutics (NASDAQ:OREX) Wednesday that it will be raising capital in the form of an equity offering came as little surprise to investors, … Continue Reading
Read nowAbraxane Data, Earnings Release Rally CELG; Back to Highs by Year End?
Long Ideas - In separate press releases on Thursday morning, Celgene (NASDAQ:CELG) reported 3Q results and announced that Abraxane demonstrated a statistically significant improvement in Progression Free Survival (PFS) … Continue Reading
Read nowDSCO Perpetually Disappoints; Surfaxin Launch Delayed
Quick Picks - While Discovery Laboratories (NASDAQ:DSCO) maintains that Afectair will hit the market in December, the launch of Surfaxin has been delayed until at least the second … Continue Reading
Read nowAnalysts Raising QCOR Price Targets, Confirming PropThink’s Valuation
Quick Picks - Price targets are rising for Questcor Pharmaceuticals (NASDAQ:QCOR) on Wednesday following the company’s third quarter earnings beat. The revised sell-side expectations support PropThink’s target price … Continue Reading
Read nowOral Remodulin Rejection A Broader Problem; Continue To Sell
Quick Picks - United Therapeutics Corporation (NADSAQ:UTHR) announced after hours on Tuesday that it’s application for an oral formulation of Remodulin (treprostinil) received a Complete Response Letter (CRL) from the … Continue Reading
Read nowARIA Bounces After Morning Downgrade
Long Ideas - Shares of ARIAD Pharmaceuticals (NASDAQ:ARIA) were under pressure Tuesday following a downgrade from Oppenheimer, which lowered ARIA from Outperform to Perform with a $23 price … Continue Reading
Read now